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Candida albicans is a prevalent fungal pathogen amongst the immunocompromised population, causing both
superficial and life-threatening infections. Since C. albicans is diploid, classical transmission genetics can not be
performed to study specific aspects of its biology and pathogenesis. Here, we exploit the diploid status of C. albicans
by constructing a library of 2,868 heterozygous deletion mutants and screening this collection using 35 known or novel
compounds to survey chemically induced haploinsufficiency in the pathogen. In this reverse genetic assay termed the
fitness test, genes related to the mechanism of action of the probe compounds are clearly identified, supporting their
functional roles and genetic interactions. In this report, chemical–genetic relationships are provided for multiple FDA-
approved antifungal drugs (fluconazole, voriconazole, caspofungin, 5-fluorocytosine, and amphotericin B) as well as
additional compounds targeting ergosterol, fatty acid and sphingolipid biosynthesis, microtubules, actin, secretion,
rRNA processing, translation, glycosylation, and protein folding mechanisms. We also demonstrate how chemically
induced haploinsufficiency profiles can be used to identify the mechanism of action of novel antifungal agents,
thereby illustrating the potential utility of this approach to antifungal drug discovery.
Citation: Xu D, Jiang B, Ketela T, Lemieux S, Veillette K (2007) Genome-wide fitness test and mechanism-of-action studies of inhibitory compounds in Candida albicans. PLoS
Pathog 3(6): e92. doi:10.1371/journal.ppat.0030092
Introduction
Candida albicans is responsible for approximately 50% of all
human life-threatening nosocomial fungal infections [1,2].
Completion of its diploid genome sequence [3,4] now
provides a foundation for studies on C. albicans biology and
pathogenesis, and offers new opportunities for therapeutic
intervention. Critical to such activities, however, remains the
task of functionally annotating the C. albicans genome. To
date, genomic studies reveal signiﬁcant differences in
genomic organization [3–5] and gene essentiality [6] between
C. albicans and Saccharomyces cerevisiae. In part, these differ-
ences reﬂect their evolutionary divergence and distinct
lifestyle as an opportunistic fungal pathogen versus a
saprophytic yeast, respectively. Unlike S. cerevisiae, a major
impediment to large-scale genetic analyses in C. albicans is the
limited ability to perform classical genetic screens, due to its
natural diploid state and lack of an easily manipulated sexual
cycle. Thus, alternative genetic strategies are required.
The phenomenon of haploinsufﬁciency (HI)—that is,
growth phenotypes associated with the loss of function (e.g.,
deletion) of one allele in a diploid—is widespread amongst
eukaryotes [7] and has been effectively applied in C. albicans to
screen for genes involved in ﬁlamentous growth [8]. HI has
been studied extensively in S. cerevisiae and offers a way to
exploit the diploidy of C. albicans. While only ;3% of the S.
cerevisiae genome displays HI under the standard growth
conditions [9], chemically induced HI is more speciﬁc. It has
been shown in an assay termed the ﬁtness test (also referred
to as haploinsufﬁcient phenotype assay) that target-speciﬁc
inhibitory molecules typically induce a growth disadvantage
(i.e., hypersensitivity) of heterozygous deletion strains corre-
sponding to the drug targets and/or other mechanism of
action (MOA)–related genes [10–14]. If this speciﬁcity is also
prevalent in C. albicans, chemically induced HI by mechanis-
tically characterized inhibitors could be used to identify
essential cellular processes and genetic interactions relevant
to this pathogen. Conversely, when a novel inhibitory
compound is tested, the response (hypersensitivity and
resistance; i.e., haploinsufﬁciency and haploproﬁciency,
respectively) of speciﬁc heterozygous strains may provide
phenotypic information reﬂecting the MOA of the com-
pound.
Here, we report on the application of chemically induced
HI on a genomic scale in C. albicans. Drawing from analogous
studies performed in S. cerevisiae, we term this assay the C.
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constructed 2,868 heterozygous deletion strains in which two
unique barcodes were introduced in the up- and downstream
regions of the deleted allele. Gene-speciﬁc barcodes differ-
entiate heterozygotes from one another and enable their
multiplex screening for HI growth phenotypes when chal-
lenged with antifungal agents. To readout growth changes
resulting from drug treatment, each unique tag is ampliﬁed
by PCR using common ﬂanking primer sequences, labeled,
and hybridized to a DNA microarray that identiﬁes all
barcodes (Figure 1). Statistical analyses enable identiﬁcation
of strains signiﬁcantly affected in growth rate. With a CaFT of
;45% genome coverage, we have examined mechanistically
diverse inhibitory compounds with three objectives: 1) to
determine and validate the prevalence and speciﬁcity of
chemically induced HI in the pathogen, 2) to provide
experimental data to functionally annotate genes and their
genetic interactions involved in the cellular processes
inhibited by these compounds, and 3) to establish the utility
of the CaFT in MOA studies of inhibitory compounds for
antifungal drug discovery.
Results
C. albicans genes selected for construction of heterozygous
deletion strains in this pilot study were chosen based on 1)
their predicted orthologs being essential in S. cerevisiae, 2)
their broad conservation across fungi (including Aspergillus
fumigatus), and/or 3) sharing strong homology to genes
conserved in higher eukaryotes. Approximately 29% of the
C. albicans genes used are essential for viability [6], and Table
S1 lists all genes examined in this study. Heterozygous
deletion strains were constructed using previously described
PCR methodologies [6]. A pool containing equal proportions
of all 2,868 strains was prepared and aliquots frozen, with
thawed aliquots used to perform all the CaFT experiments
described. To identify speciﬁc haploinsufﬁciency and/or
haploproﬁciency, a normalized z-score was used to assess
the response of individual strains to inhibitory compounds
(see Materials and Methods for details). For each strain, the
normalized z-scores of both barcodes are determined by 1)
the average (‘‘historical’’) behavior of this strain, as deter-
mined by each barcode, in a set of reference experiments
with chemically diverse compounds (i.e., barcode-speciﬁc
error modeling), and 2) the overall responsiveness of all the
strains in a given experiment. Since the up- and down-
barcodes are analyzed separately, individual strains are
independently appraised twice in each experiment. A positive
normalized z-score indicates a relative decrease in abundance
in the compound-treated culture (i.e., insufﬁciency or hyper-
sensitivity) and a negative normalized z-score indicates a
Figure 1. An Overview of the CaFT
Individual heterozygous deletion strains contain two unique barcodes, up-tags (red) and down-tags (blue), flanked by two pairs of common primer
sequences (black for all the up-tags, grey for all the down-tags) at the deleted allele. The CaFT pool contains 2,868 strains, representing ;45% of the C.
albicans genome. Aliquots of the pool are treated with an inhibitory compound (at different concentrations) or a mock treatment over 20 population
doublings. The relative abundance of each strain is subsequently monitored by DNA microarrays competitively hybridized with amplified and labeled
tags (using the common primer pairs) from the two treatments. The response of each strain to the compound is appraised by a normalized z-score, with
a positive value indicating hypersensitivity, and a negative value relative resistance.
doi:10.1371/journal.ppat.0030092.g001
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Author Summary
Candida albicans is the principal human fungal pathogen respon-
sible for life-threatening fungal infections. Despite an urgent need
for more efficacious antifungal agents, the pace of discovery has
waned using the traditional approaches. In part, this reflects the
longstanding limitation of performing mechanism-of-action–based
screening directly in those key fungal pathogens for which new
antifungal agents are sought. Here we describe an alternative
approach, first developed in Saccharomyces cerevisiae and termed
the fitness test, to survey approximately 45% of the C. albicans
genome for the molecular targets of growth inhibitory compounds.
We demonstrate that mechanistically characterized compounds can
be used as chemical probes to assist gene function annotations in C.
albicans. Similarly, fitness tests performed using newly discovered
compounds provide powerful insights into their mechanism of
action and therapeutic potential as antifungal agents. Extending this
screening paradigm to C. albicans facilitates a pathogen-focused
approach to antifungal drug discovery.relative increase (i.e., proﬁciency or resistance). To fully
examine the effects elicited by any compound, experiments
were performed at multiple sub-lethal inhibitory concen-
trations (ICs). A series of known antifungal agents with well-
characterized MOAs were tested to validate the CaFT. Several
of these compounds have been previously examined in the S.
cerevisiae ﬁtness test (ScFT), and they enable classiﬁcation of
functionally orthologous genes between organisms.
CaFT Profiling of Inhibitors of Ergosterol Biosynthesis
The CaFT strain pool includes heterozygotes for all but
three genes involved in the ergosterol biosynthetic pathway
(Figure 2A). This pathway represents a well-characterized
target for antifungal agents (for a review see [15]) and
provides an opportunity to determine the speciﬁcity of
chemically induced HI in C. albicans by conventional methods
(spot tests) and the CaFT.
Fluconazole is clinically used to treat C. albicans infections.
It inhibits the sterol 14a-demethylase, which is encoded by
ERG11. (Note that we use standard gene names as appear in
the Candida Genome Database and MycoPathPD, with orf19
designations given in the appropriate ﬁgure legends, and that
the preﬁx Sc is used to refer to S. cerevisiae genes.) The
heterozygous deletion strains for genes involved in ergosterol
biosynthesis were tested against ﬂuconazole by spot tests at
multiple concentrations. While none showed signiﬁcant HI
under the standard growth conditions, the ERG11 and NCP1
(encoding a NADP-cytochrome P450 reductase required for
the Erg11p function) strains displayed speciﬁc hypersensitiv-
ity to ﬂuconazole (Figure 2A). Similarly, both strains showed
ﬂuconazole-induced HI in the CaFT over a wide range of ICs,
as their z-scores were signiﬁcantly differentiated from the
population (Figure 2B and 2C; a summary of all the CaFT
results described is provided in Table S1.) Two additional
hypersensitive strains detected are CDR1 and PDR17 (orthol-
ogous genes in S. cerevisiae are ScPDR5 and ScPDR16,
respectively; note that the other ortholog of ScPDR16,
orf19.1027, was not present in the pool). In addition, the
ERG6 strain showed relative resistance as indicated by the
signiﬁcant negative z-scores at higher concentrations (Figure
2C). The responses of these strains to ﬂuconazole were
conﬁrmed by the spot tests (Figure 2D). Although over-
expression of efﬂux pump genes (CDR1, CDR2, and MDR1)
and PDR16 (encoding a phosphatidylinositol transfer pro-
tein) was detected in ﬂuconazole-resistant clinical isolates,
only CDR1 and PDR16 have been correlated directly to
resistance [16,17]. The strains for CDR2 and MDR1 showed no
hypersensitivity to ﬂuconazole in the CaFT (Table S1) or spot
tests (Figure 2D), whereas homozygous deletion strains for
CDR1 and PDR17 were markedly more susceptible to
ﬂuconazole (Figure 2E).
The ﬁve strains identiﬁed with ﬂuconazole in the CaFT
represent different aspects of its MOA: the drug target
(Erg11p) and its accessory protein (Ncp1p), the principal
efﬂux pump (Cdr1p), and two additional factors, Pdr17p and
Erg6p, that are likely involved in drug uptake [18,19]. Another
triazole (voriconazole) and imidazoles (ketoconazole, clotri-
mazole, econazole, and sulconazole) yielded similar CaFT
proﬁles (Figure S1). The proﬁles of additional inhibitors of
ergosterol biosynthesis, including terbinaﬁne, lovastatin, and
dyclonine, are described in Text S1 (Figure S2 and Table S1),
and their results largely corroborate those determined in the
ScFT [13]. Inhibitors that do not act through speciﬁc protein
targets were also examined, including amphotericin B, which
binds preferentially to ergosterol in the plasma membrane of
fungi, and two toxic ergosterol analogs (ECC69 and
ECC1384). In each case, complex CaFT proﬁles affecting
multiple aspects of metabolism and membrane-related
functions were produced but with no clear target(s) resolved
(Figure S3).
CaFT Profiling of Inhibitors of Other Enzymes and Protein
Complexes
The CaFT proﬁles of enzyme inhibitors are usually concise.
For example, ALG7 and AUR1 heterozygotes correspond to
the target gene of tunicamycin and aureobasidin A, respec-
tively, and each displayed highly signiﬁcant and speciﬁc
hypersensitivity to its cognate inhibitor (Figure S4). Similarly,
the catalytic subunit (FKS1) and the regulatory subunit
(RHO1) of glucan synthase were identiﬁed in the CaFT with
their cognate inhibitors, caspofungin and ergokonin A
(Figure S5). Brefeldin A is unusual in that it binds to the
interface of two proteins, both of which are members of two
protein families in C. albicans. Despite such apparent
complexity, a single target pair, SEC7 and ARF2, was robustly
identiﬁed in the CaFT (Figure S6).
Cerulenin speciﬁcally inhibits the condensation reaction
associated with the a subunit of the fatty acid synthase (FAS),
a heteromultimeric complex of a (Fas2p) and b (Fas1p)
subunits. Although not examined in the ScFT, cerulenin
elicited reproducibly speciﬁc hypersensitivity of the FAS1
strain but not of FAS2, even at the highest drug concentration
tested (Figure 3A). These results were also demonstrated by
spot tests (Figure 3B). In S. cerevisiae, the expression of ScFAS2
is regulated in an ScFas1p-dependent manner to control the
stoichiometry of the FAS complex [20]. Our results suggest
that a similar regulatory mechanism exists in C. albicans, with
the level of Fas1p being the critical factor controlling the FAS
complex (see Figure 3C and Discussion). Consistent with this
model, only FAS1 exhibits HI under the standard growth
conditions (Figure 3B and 3D).
Failure to detect hypersensitivity of the FAS2 heterozygote
to cerulenin reﬂects a more general difﬁculty in correctly
identifying chemically induced HI within protein complexes,
due to regulation of subunit stoichiometry, its assembly, or
activation. To further investigate these potential issues,
additional reference compounds that inhibit distinct protein
complexes were examined.
Microtubules are comprised of a- and b-tubulin subunits
encoded by TUB1 and TUB2, respectively. A potential binding
site for benomyl, a microtubule depolymerizing agent, has
been suggested in the core of S. cerevisiae b-tubulin [22], and
the heterozygous deletion strains for both ScTUB1 and
ScTUB2 are benomyl hypersensitive [23]. In the CaFT,
however, only the TUB1 strain displayed signiﬁcant hyper-
sensitivity to benomyl, as well as to additional microtubule
inhibitors, including nocodazole, mebendazole, and thiaben-
dazole, while the TUB2 strain was marginally hypersensitive
only to nocodazole (Figure 4A and unpublished data; note
that TUB4, orf19.1238, was not represented in the CaFT). Spot
tests conﬁrmed the hypersensitivity of the TUB1 strain and
the lack of benomyl-induced HI for TUB2 (Figure 4B). The
lack of speciﬁc hypersensitivity of the TUB2 heterozygote to
most, if not all, of the microtubule inhibitors tested raises the
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Fitness Test and MOA Studies in C. albicansFigure 2. Characterization of Fluconazole-Induced HI by Spot Tests and CaFT Profiling
(A) Specificity of chemically induced HI by fluconazole as determined by spot tests. The heterozygous deletion strains corresponding to genes involved
in the ergosterol biosynthesis pathway were tested against fluconazole at 0.75 lg/ml. Note that the two underlined strains, CYB5 (orf19.7049) and ERG4
(orf19.5379), were not present in the CaFT pool and that an ERG9 (orf19.3616) strain was not constructed. The HIS3 strain is used throughout this study as
the wild-type control, since the HIS3 gene, as an auxotrophic marker, was used to construct all the heterozygous deletion strains (see Materials and
Methods).
(B) CaFT profile of fluconazole at 0.162 lg/ml (with fitness, F, value of 0.80; i.e., IC20). The x-axis represents the strains in the CaFT pool, and y-axis the
normalized z-scores of the corresponding strain in this experiment. (Although the z-scores of both up- and down-barcodes are assessed independently
for each strain, the higher of the two was selected for display.) Significant outliers are highlighted by filled symbols, as their z-scores deviate significantly
from the population. The z-scores of two groups of strains, corresponding to other genes involved in ergosterol biosynthesis or potential efflux pumps,
are highlighted by open symbols.
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subunits is regulated in C. albicans. In yeast, overexpression
of ScTUB2 results in lethality, whereas overexpression of
ScTUB1 does not [24]. Moreover, mutations in ScTUB1 and
ScTUB2 are known for their unlinked noncomplementation
[25]. In contrast, only an ScTUB1 heterozygote is reported to
be defective under the standard growth conditions [23,26]. In
C. albicans, heterozygosity of both TUB1 and TUB2 confers
growth defects (Figure 4C). Although stoichiometric regu-
lation of tubulins in C. albicans is unknown, it may confound
the chemically induced HI phenotypes associated with TUB1
and TUB2.
Radicicol inhibits cell growth by competitively binding to
the conserved chaperone, HSP90 [28], a key molecular
chaperone that, together with its co-chaperones, facilitates
proper folding of multiple client proteins [29]. Unlike S.
cerevisiae, which contains two HSP90 proteins, ScHsc82p and
ScHsp82p, C. albicans possesses only one. Despite sharing all
the conserved amino acid residues in both yeast HSP90
proteins implicated in radicicol binding [28], the HSP90
heterozygous deletion strain lacked detectable hypersensitiv-
ity when tested in the CaFT (Figure 5A) or when examined
either by spot tests (Figure 5B) or liquid IC determination
(unpublished data). Instead, three (SGT1, CDC37, and CNS1) of
the ﬁve potential Hsp90p-associated co-chaperones (CPR6
and orf19.7602 are also represented in the CaFT) displayed HI
to radicicol (Figure 5A and 5B). Interestingly, the three yeast
orthologs, ScSgt1p, ScCdc37p, and ScCns1p, all physically and
genetically interact with ScHsc82p and/or ScHsp82p [30,31].
Although radicicol-induced HI of HSP90 was not detected,
the CaFT proﬁles reﬂected other aspect of the target; that is,
activation of Hsp90p by its co-chaperones (see Discussion).
Additional inhibitors of protein complexes tested with
informative mechanistic CaFT proﬁles included cytochalasin
D, roridin A, and verrucarin A. Cytochalasin D inhibits both
association and dissociation of actin ﬁlaments in vitro. The
CaFT results reveal a particular aspect of actin polymer-
ization affected in vivo by cytochalasin D, namely, the
branching of actin cables to produce cortical actin, as
multiple members of the ARP2/3 complex showed markedly
Figure 3. CaFT Profiling and Characterization of Cerulenin-Induced HI
(A) CaFT profiles of cerulenin, with highlighted strains as follows: FAS1 (orf19.979), FAS2 (orf19.5949), and MDR1 (orf19.5604). A homozygous deletion of
MDR1 is hypersensitive to cerulenin [21]; however, the heterozygous deletion strain showed no specific hypersensitivity at the ICs tested in the CaFT.
(B) The spot tests of selected heterozygous deletion strains against cerulenin. Note that the hypersensitivity of the MDR1 strain was only seen at the
highest concentration of cerulenin tested.
(C) A model for regulating stoichiometry of the FAS complex in S. cerevisiae. As shown by Wenz et al. [20], the expression of ScFAS2 is repressed by an
unknown transcription repressor (rep. X), which is in turn derepressed by free b subunit (Fas1p). According to this model, ScFAS2 expression is
dependent on free Fas1p to control the normal stoichiometry of the FAS complex. A similar regulatory mechanism in C. albicans may explain the
observed cerulenin-induced HI of FAS1 but not FAS2 (see text for details).
(D) FAS1 is haploinsufficient under the standard growth conditions. In order to determine HI, cultures of the selected strains were first incubated for 6 h
(reaching exponential growth) and then diluted to an OD600 of 0.005. The fresh cultures were incubated for another 12 h, after which the OD was
monitored for an additional 4 h.
doi:10.1371/journal.ppat.0030092.g003
(C) CaFT profiles of fluconazole at different concentrations, with corresponding F values and ICs (in parentheses). In order to simplify a given CaFT
profile, all the z-scores are displayed one-dimensionally according to the values but regardless of strain identities. Selected strains are marked so that
their z-scores can be compared with the population and between experiments. Note that clotrimazole-induced HI of CDR1 and PDR16 was
independently observed in the ScFT [13].
(D) Spot tests of heterozygous deletion strains identified in the CaFT (CDR1, PDR17, and ERG6) and the CDR2 and MDR1 strains (for their relevance, see
the text) against multiple fluconazole concentrations.
(E) Spot tests of homozygous deletion strains against fluconazole. (The orf19 designations are as follows: ERG11¼orf19.922, NCP1¼orf19.2672, CDR1¼
orf19.6000, PDR17 ¼ orf19.5839, ERG6 ¼ orf19.1631, CDR2 ¼ orf19.5958, MDR1 ¼ orf19.5604, FCR1 ¼ orf19.6817.)
doi:10.1371/journal.ppat.0030092.g002
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Fitness Test and MOA Studies in C. albicansHI (Figure S7). The structurally related mycotoxins roridin A
and verrucarin A both noticeably affected multiple subunits
of the initiation factor eIF3 complex (Figure S8).
CaFT Profiling and MOA Studies of 5-Fluorouracil, 5-
Fluorocytosine, and Tubercidin
The preceding examples demonstrate the speciﬁcity of
chemically induced HI and the biological relevance of
information contained within CaFT proﬁles; that is, small
molecules that selectively inhibit proteins or protein com-
plexes typically elicit speciﬁc CaFT proﬁles comprising the
target proteins and/or other factors that functionally interact
with the targets. The base analogs, 5-ﬂuorocytosine (5-FC)
and 5-ﬂuorouracil (5-FU), on the other hand, do not exert
inhibitory effects directly on speciﬁc proteins. We tested
whether both analogs and tubercidin (7-deazaadenosine)
elicit speciﬁc HI indicative of their MOAs. 5-FC and 5-FU
Figure 5. CaFT Profiles and Spot Tests of Radicicol
(A) CaFT profiles of radicicol with genes encoding co-chaperones of Hsp90p highlighted, including SGT1 (orf19.4089), CDC37 (orf19.5531), CNS1
(orf19.6052), orf19.7602 (an ortholog of ScAHA1), and CPR6 (orf19.7654) ([30] and references therein). Radicicol also elicited HI of ERG27 (orf19.3240), CDR1
(orf19.6000, an efflux pump), and PRS1 (orf19.1575, involved in cell integrity/stress signaling as reported [32]).
(B) Spot tests of radicicol against heterozygous deletion strains corresponding to HSP90 and its co-chaperones.
doi:10.1371/journal.ppat.0030092.g005
Figure 4. CaFT Profiles of Microtubule Inhibitors
(A) CaFT profiles of nocodazole, benomyl, mebendazole and thiabendazole. Note that the ScFT experiments with these compounds have not been
reported. Highlighted, in addition to TUB1 (orf19.7308) and TUB2 (orf19.6034), are BUB1 (orf19.2678), MAD2 (orf19.1040) and ESP1 (orf19.3356) strains that
showed modest but reproducible hypersensitivity to nocodazole. The corresponding proteins are involved in mitotic checkpoint regulation and spindle
pole body assembly [27]. Their relevance becomes apparent in the results described in Figure 7.
(B) Spot tests of heterozygous deletion strains highlighted in (A) against benomyl. Note the lack of hypersensitivity of TUB2 in spot tests is consistent
with the CaFT results, implying that the failure to detect hypersensitivity of the TUB2 strain in the CaFT is not due to poor performance of the barcodes.
(C) TUB1 and TUB2 strains are haploinsufficient under the standard growth conditions (see Figure 3 legend for experimental details).
doi:10.1371/journal.ppat.0030092.g004
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Fitness Test and MOA Studies in C. albicansare pro-drugs whose MOA has been well characterized in S.
cerevisiae and to a lesser extent in C. albicans (see below). 5-FC,
once inside the cell, is converted to 5-FU by cytosine
deaminase, and 5-FU to 5-FUMP by uracil phosphoribosyl-
transferase (UPRT). Both enzymes are part of the pyrimidine
salvage pathway (Figure 6A). 5-FU, in the ScFT, has been
shown to induce HI of several genes involved in rRNA
processing and ribosomal biogenesis [11,13]. In the CaFT, 5-
FU, 5-FC, and tubercidin elicited responses of two distinct
groups of heterozygous deletion strains, reﬂecting collectively
a common MOA. While the majority of hypersensitive strains
correspond to genes whose S. cerevisiae orthologs are involved
in biogenesis of the 60S ribosomal subunit, resistant strains
predominantly correspond to those encoding protein sub-
units of the U3 snoRNP complex, which is required for 18S
rRNA processing (Figure S9). As ribosomal RNAs account for
over 80% of the total cellular RNA, the preferential effects on
rRNA biogenesis by these inhibitors may simply reﬂect the
relative abundance of rRNAs. Another analog of uracil, 6-
azauracil (6-AU, known to inhibit the IMP dehydrogenase
involved in purine biosynthesis [33]), on the other hand, did
not produce a ribosomal biogenesis–related proﬁle (Figure
S9A). The distinct CaFT proﬁles between 6-AU and 5-FC, 5-
FU, or tubercidin suggest that a more speciﬁc mechanism
may be involved (see Discussion).
The CaFT proﬁles of 5-FU and 5-FC also provide
mechanistic insights into their uptake and metabolism.
Counterintuitively, 5-FC is over 200-fold more potent than
5-FU (Figure 6C and 6D). The underlying mechanism for this
difference is revealed in their CaFT proﬁles. FCY2 encodes a
Figure 6. Genetic Characterization of 5-FC and 5-FU in C. albicans
(A) Pyrimidine salvage pathway, and transport and metabolism of 5-FC (see text for details).
(B) A hypothesis that fluorinated uracil blocks the formation of pseudouridine in rRNA. Note that pseudouridines are a prerequisite for ribosomal RNA
processing [34].
(C and D) Functional characterization of potential permeases or transporters involved in the uptake of 5-FC (C) and 5-FU (D). A homozygous deletion
strain for FCY2 (distinguished by the asterisk) and conditional shut-off (tetracycline repressible promoter, GRACE) strains [6] for genes indicated were
tested in the absence (i.e., the non-repressing conditions, top panels) or the presence (i.e., the repressing conditions, bottom panels) of 100 lg/ml
tetracycline against both compounds at the concentrations indicated. Note that 1) in (C) the FCY2 homozygous deletion strain was resistant to 5-FC,
and 2) in (D) only the FCY21 GRACE strain exhibited slightly increased susceptibility to 5-FU under the non-repressing condition, suggesting that
overexpression of FCY21 (from the tetracycline promoter, as observed in other cases, unpublished observations) may marginally facilitate the uptake of
5-FU.
(E) Suppression of 5-FC (top) and 5-FU (bottom) antifungal activity by genetic depletion of Fur1p. The FUR1 and HIS3 (the control) GRACE strains were
grown in the presence (100 lg/ml, þTET) or absence ( TET) of tetracycline with 5-FC or 5-FU at the concentrations indicated. Individual growth was
normalized with growth of the HIS3 strain without antifungal drug in the presence or absence of tetracycline. Note that when the expression of FUR1
was repressed, the strain was markedly resistant to both compounds, whereas it was modestly hypersensitive under the non-repressing conditions,
likely due to overexpression of FUR1 from the tetracycline promoter. (The orf19 designations are as follows: FCY2¼orf19.1357, FCY21¼orf19.333, NNT1¼
orf19.4118, DIP5 ¼ orf19.2445, and FUR1 ¼ orf19.2640.)
doi:10.1371/journal.ppat.0030092.g006
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heterozygous deletion strain displayed speciﬁc and signiﬁcant
resistance to 5-FC, but not to 5-FU or tubercidin (Figure
S9A). A homozygous deletion of FCY2 was highly and
speciﬁcally resistant to 5-FC (Figures 6C, 6D, and S9B),
suggesting a direct and speciﬁc role of Fcy2p in transporting
5-FC. In contrast, 5-FU may enter the cell by passive diffusion
(Figure 6D), hence the relatively low potency. Similarly, the
nucleoside transporter Nnt1p (absent in S. cerevisiae) was
identiﬁed as responsible for the uptake of tubercidin (Figure
S9B). Another notable resistant strain identiﬁed in the CaFT
proﬁles of both 5-FC and 5-FU corresponds to FUR1 (Figure
S9A). FUR1 encodes UPRT that converts both pro-drugs to 5-
FUMP (Figure 6A). A loss of function of FUR1 is expected to
confer resistance to both 5-FC and 5-FU, as demonstrated by
the high level resistance of a FUR1 conditional shut-off strain
under the repressing conditions (Figure 6E). These results
predict speciﬁc resistance mechanisms that are known for 5-
FC. Since the pyrimidine salvage pathway (Figure 6A) is not
essential when the de novo pathway is intact, any loss-of-
function mutations in genes involved in the former may have
no effect on viability, and yet they may confer speciﬁc
resistance, as demonstrated by mutations in the uptake and/
or metabolism of this compound in S. cerevisiae (e.g., [35]) and,
more importantly, in clinical isolates of C. albicans (e.g.,
[36,37]). This may also account for the primary resistance in
C. albicans; that is, the inherent resistance to 5-FC without
prior exposure, which is observed in ;3% of clinical isolates
[38].
Novel Antifungal Compounds That Affect Microtubule
Dynamics
Mechanisms inferred from screening known antifungal
agents in the ﬁtness tests of S. cerevisiae and C. albicans imply
that MOA information could similarly be obtained for new
compounds. To test this possibility, we examined a group of
chemically related active compounds with unknown MOA
(Figure 7A). CaFT proﬁles identiﬁed the TUB1 strain as
strikingly hypersensitive to all compounds examined (Figure
7B). Distinct secondary hypersensitivity, including hetero-
zygotes compromised for mitotic checkpoint and cortical
actin function, enabled compounds to be grouped into three
Figure 7. CaFT Profiling and Characterization of Novel Antifungal Compounds
(A and B) Chemical structures (A) and the CaFT profiles (B) of novel and structurally related compounds that are predicted to affect microtubule
dynamics.
(C) Spot tests of representative compounds (ECC220, ECC284, and ECC275) confirm hypersensitivity detected in the CaFT. For orf19 designation, see
Figure 4.
doi:10.1371/journal.ppat.0030092.g007
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each class were examined in spot tests, which largely
conﬁrmed the CaFT results (Figure 7C). Compared with
known microtubule inhibitors (Figure 4), the CaFT proﬁling
suggested that these compounds inhibit growth, likely by
affecting the microtubule function.
To further characterize the MOA of these compounds,
multiple microtubule-based secondary assays were per-
formed. Microtubules form the core structural component
of the nuclear mitotic spindle and are necessary for
chromosomal movement. In the yeast, the movement of
nuclei to the bud neck before mitosis and the subsequent
separation of nuclei depend on cytoplasmic microtubules
[39,40]. In the wild-type cells, these events occur in a highly
coordinated cell cycle–dependent manner such that the
large-budded cells are almost never observed without the
nucleus at, or extended through, the bud neck. As nuclear
migration defects associated with microtubule perturbation
can readily be visualized by DAPI staining of DNA, we
examined the terminal phenotypes associated with a TUB1
conditional shut-off strain and compared them with those
observed in the wild-type C. albicans cells chemically inhibited
with benomyl, nocodazole, and representative compounds
from each sub-class (ECC85, ECC248, and ECC275). One hour
after TUB1 repression, cell division and nuclear migration
were largely arrested in the majority of the cells examined, as
large-budded cells were predominantly observed, with nu-
clear staining being restricted to the mother cell (Figure 8A).
To visualize microtubules, a C. albicans strain carrying a
Tub1p-GFP fusion (under the TUB1 promoter, otherwise
indistinguishable from the wild-type parental strain) was used
to compare the effects of known microtubule inhibitors
versus these ECC compounds. In the mock-treated (1%
DMSO) cells, two distinct sub-cellular microtubule structures
were observed depending on the cell cycle: the mitotic
spindles (visualized in the large-budded cells) and the spindle-
pole bodies (visualized prominently in the small-budded cells)
(Figure 8B). As expected, benomyl and nocodazole ablated
the mitotic spindles, resulting in patches or aggregates of
tubulin. Defects in nuclear division and G2 cell cycle arrest, as
well as a more pronounced ﬁlamentous growth, were also
observed (Figure 8C and 8D). These results are in agreement
with the previous observations [41,42] and establish a strong
phenotypic correlation between genetic depletion and
chemical inhibition of the tubulin function. The defects
caused by ECC85 (Figure 8E), ECC248 (Figure 8F), and
ECC275 (unpublished data) were similar to those, described
above, seen for cells treated with nocodazole, benomyl, or
genetically depleted for TUB1. However, cells treated with the
control compounds ﬂuconazole (Figure 8G) and amphoter-
icin B (unpublished data) lacked microtubule and/or cell cycle
defects. To address whether the representative compounds of
each ECC sub-class directly inhibit microtubule polymer-
ization, their effects on in vitro bovine microtubule polymer-
ization were examined. ECC85, ECC248, and ECC275 each
displayed a dose-dependent inhibition of microtubule poly-
merization. Moreover, the IC50 (of Vmax) of ECC85 and
ECC248 was approximately three times lower that of
nocodazole (Figure S10). Collectively, these data provide in
vitro and in vivo evidence that these compounds perturb the
function of microtubules in C. albicans.
Discussion
The impact of the baker’s yeast, S. cerevisiae, as a eukaryotic
model system in biology is immense. Indeed, the extensive
knowledge base of biological information gained from these
studies has greatly facilitated our understanding of fungal
biology in medically signiﬁcant pathogens, including C.
albicans (e.g., [3,4,6,8]) and A. fumigatus (e.g., [43,44]). However,
the differences in lifestyles and the functional disconcord-
ance at the genomic level between yeast and fungi [6,8],
combined with the extensive genome sequence information
across the fungal kingdom that is now available [45–48],
provide a timely opportunity to develop fungal genomics
tools for basic and applied research in this ﬁeld. The CaFT,
based on the chemically induced responses of heterozygous
deletion strains, exploits the diploid nature of C. albicans and
provides a global genetic strategy to directly perform such
studies in this pathogen.
The genetic basis of the ﬁtness test is the consequence of
heterozygosity in the presence of an inhibitory compound,
and hence its readout is based on observable phenotypes and
is often concise. As ﬁrst reported in S. cerevisiae [11–13],
chemically induced HI is largely restricted to the target and
to other genes whose functions are genetically associated with
the target and/or MOA of the inhibitor. This is in stark
contrast with results of expression proﬁling of inhibitory
compounds. Examination of the transcriptional responses of
either S. cerevisiae or C. albicans to azoles revealed nearly 300
signiﬁcantly responsive genes [49,50]. Although many genes in
the ergosterol pathway are included in these complex
proﬁles, there is a lack of clear quantitative correlation
between the level of responsiveness and their biological
relevance to the primary MOA of azoles. The CaFT proﬁles of
ﬂuconazole, however, contain only ﬁve signiﬁcant responsive
genes corresponding to the target (Erg11p), its accessory
factor (Ncp1p), the principal efﬂux pump (Cdr1p), and two
additional factors involved in drug uptake (Pdr17p and
Erg6p, Figure 2). For most reference compounds examined,
signiﬁcantly responsive strains identiﬁed in the CaFT were
validated independently, suggesting a low rate of false
positives and the effectiveness of the statistical analyses
employed.
Enzyme inhibitors such as azoles, terbinaﬁne, dyclonine,
tunicamycin, aureobasidin A, glucan synthase inhibitors, and
brefeldin A all induce signiﬁcant and speciﬁc hypersensitivity
of heterozygotes corresponding to their targets (including co-
factors and regulatory subunits) in the CaFT. Thus, a
compelling indication of MOA is generally achieved. Cer-
ulenin is an exception to this trend, as its known target, FAS2,
showed no HI. Instead, the heterozygote for the other subunit
of the FAS complex, FAS1, was noticeably hypersensitive.
These results are consistent with the Fas1p-dependent
stoichiometric regulation of the FAS complex demonstrated
in S. cerevisiae [20]. We speculate that a FAS1 strain is
speciﬁcally hypersensitive to cerulenin because only in this
strain is the overall level of the FAS complex compromised,
whereas Fas2p levels in the FAS2 heterozygote are likely
upregulated by normal levels of Fas1p to restore the wild-type
levels of the FAS complex (see Figure 3C for details).
Inhibitors of protein complexes, such as cytochalasin D
(Figure S7), roridin A, and verrucarin A (Figure S8), typically
produced CaFT proﬁles reﬂecting a rich diversity of bio-
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known MOAs. Despite this, discerning the speciﬁc subunit
targeted within a complex is problematic, as multiple
components of the complex are routinely observed as
chemically haploinsufﬁcient. Thus, CaFT proﬁling only
yielded a general classiﬁcation of MOA (ARP2/3-based
cortical actin assembly and eIF3-directed translation, respec-
tively), and further studies would be required to reﬁne their
molecular targets. Radicicol provides another cogent exam-
ple of the limitation of the CaFT, in that its well-
characterized target (Hsp90p) was unresponsive to drug
treatment as a heterozygote (Figure 5). Instead, strains for
its co-chaperones were identiﬁed as radicicol sensitive. These
results are consistent with the observations that, in S.
cerevisiae, the activity of Hsp90p is regulated at the post-
transcriptional level; that is, it is activated by its co-
chaperones [29]. Similar regulatory control of Hsp90p in C.
albicans would account for our observations.
Mechanistic insights of ﬁtness test proﬁling can also be
extended to nucleoside and base analogs ([11,13] and this
study). For example, both ScFT and CaFT proﬁling reinforce
that ribosomal RNAs are likely the primary target on which
the toxicity of 5-FU and 5-FC is exerted. It is unclear whether
rRNA processing and ribosomal biogenesis is affected largely
due to the relative abundance of rRNAs over other RNAs, or
if these compounds exert a more speciﬁc mechanism
Figure 8. MOA Characterization of Compounds That Affect Microtubule Dynamics
(A) The phenotypic defects associated with a TUB1 conditional shut-off strain [6] examined under the repressing conditions (with time after the switch
indicatedoneachphoto).Underthenon-repressingconditions,thisstrainwasindistinguishablefromthemock-treatedwild-typecells(unpublisheddata).
NuclearmigrationwasvisualizedbyDAPIstrainingwithmorphologyviewedunderNomarskioptics.In(B–G),astraincarryingaTub1p-GFPfusionwasused.
(B) The microtubule/spindle structures (as visualized by GFP-Tub1 fusion), nuclear migration/division, and morphology of the mock-treated cells.
(C–G) The microtubule/spindle structures, nuclear migration, and morphology of cells treated with benomyl (C), nocodazole (D), ECC85 (E), ECC248 (F),
and fluconazole (G). The concentrations (lg/ml, in parentheses) and incubation times are indicated on each photo.
doi:10.1371/journal.ppat.0030092.g008
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transcriptionally modiﬁed and contain a disproportionately
high number of pseudouridines, an essential modiﬁcation
produced by isomerization of uridine via base rotation and
subsequent linking of uracil to the sugar moiety at the 5
position of the pyrimidine ring (Figure 6B) [34]. Thus, rather
than a bulk ﬂow MOA for their preferential rRNA effects, a
more speciﬁc ribosomal biogenesis defect may result from the
incorporation of 5-ﬂuorinated uridine into rRNAs, thus
effectively blocking this base rotation for the formation of
pseudouridine. Consistent with this view, 6-AU, which is able
to undergo base rotation, did not yield a CaFT proﬁle
indicative of an rRNA processing MOA.
CaFT proﬁles often contain additional responsive genes,
some of which illuminate drug uptake and efﬂux mechanisms
that play important roles in acquired and inherent resistance
to antifungal drugs such as azoles and 5-FC. For example,
CDR1 displays chemically induced HI against all the azoles we
examined, as well as other predicted efﬂux substrates,
including brefeldin A, as reported [21], radicicol (Figure
5A), cytochalasin D (Figure S7), PF1163A, and latrunculin A
(unpublished data). Interestingly, the CaFT also identiﬁes
heterozygotes with a selective growth advantage (haploproﬁ-
ciency) in the presence of inhibitory compounds. This is best
illustrated by the identiﬁcation of the well-characterized
resistance mechanisms for 5-FC/5-FU in the CaFT. Hetero-
zygosity of the two genes involved in drug uptake (FCY2) and
metabolic conversion (FUR1) [35–37] result in haploproﬁ-
ciency (Figures 6 and S9). A similar role was established for
t h eu p t a k eo ft u b e r c i d i nb yN n t 1 p( F i g u r eS 9 ) .O t h e r
responsive genes may underscore their genetic interactions
with the drug targets; for example, the dependence of mitotic
checkpoint regulation and spindle pole body assembly on
microtubule integrity (nocodazole, Figure 4A; ECC85, Figure
7B), and a possible stress response associated with tunicamy-
cin (Figure S4B). Several inhibitors (radicicol, terbinaﬁne,
tunicamycin, aureobasidin A, and cytochalasin D) also induce
hypersensitivity of heterozygotes whose biological relevance
to the targets is unclear. Such hypersensitive strains may
reﬂect potential synthetic interactions between chemical
inhibition of the drug target and heterozygosity of the
second gene. Alternatively, chemically induced HI in some
cases may reﬂect potential secondary targets of these
compounds, as previously suggested [13].
In this study, over 100 C. albicans genes have been classiﬁed
according to their chemically induced HI with the ;20 types
of inhibitors tested. Although some of these genes have been
experimentally characterized in C. albicans, most are anno-
tated solely by their similarity to S. cerevisiae orthologs. Their
phenotypes in response to selected inhibitors provide a ﬁrst
level of functional annotation. This is best exempliﬁed by
screening brefeldin A, which binds to the interface of two
proteins (ARF and GEF), both of which are members of
conserved protein families in C. albicans. CaFT proﬁling
identiﬁed the functional pair that is most susceptible to
brefeldin A (Figure S6). The CaFT is, however, currently
biased against the identiﬁcation of C. albicans speciﬁc genes
for two reasons: 1) only ;3% of the genes represented in this
pilot study are Candida-speciﬁc (as deﬁned by their absence of
clear homologs in S. cerevisiae, A. fumigatus, S. pombe, or the
human genes, using a BLAST cutoff of 1 3 10
 20), and 2) the
selected probe inhibitors have intrinsic activity against both
S. cerevisiae and C. albicans, and are mechanistically conserved.
It is therefore not surprising that the majority of genes
identiﬁed in this study are conserved. Notwithstanding these
restrictions, Nnt1p, a nucleoside transporter absent in S.
cerevisiae, was identiﬁed as required for the uptake of
tubercidin in C. albicans (Figure S9), suggesting that expand-
ing genomic coverage in the CaFT and screening more
diverse inhibitory compounds will likely uncover speciﬁc
features of C. albicans biology.
Other potential limitations to the CaFT include: 1) The C.
albicans diploid genome contains allelic polymorphisms, some
of which may inactivate genes and confound their identity as
haplo-responsive strains. However, as summarized in Table
S2, failure to detect hypersensitivity of strains for target genes
(e.g., FAS2, HSP90) was not due to allelic differences, which is
only rarely observed amongst 69 other genes pertinent to the
CaFT proﬁles reported here. Although eight of these genes
possess some allelic differences, they result in only one or two
conservative amino acid change(s) in their corresponding
proteins. 2) The inherent HI under the standard growth
conditions, as demonstrated by TIF35 (Figure S8), may
obscure chemically induced HI. However, severe intrinsic
HI is rarely observed. Other heterozygotes with modest
growth defects (e.g., FAS1, TUB1) are not problematic to assay
in the ﬁtness test format. 3) The detection of strain responses
in the CaFT relies solely on robust hybridization signals of
error-free barcodes. The introduction of double barcodes
signiﬁcantly reduces the occurrence of unassayable strains
(e.g., [14]). Barcodes of such strains can be sequenced and
microarrays redesigned with fully complementary oligonu-
cleotides (e.g., [51]), or such strains can be simply recon-
structed with new barcodes. 4) In S. cerevisiae, it is known that
deletion strains can become aneuploid [52]. Our strain stocks
are stored with minimal manipulation, and the strain pool is
preserved in aliquots. All the CaFT experiments were
performed with aliquots from the same preparation.
Although the problem of aneuploidy has not been examined
in C. albicans, our standard practices should minimize its
occurrence.
We have also explored the CaFT assay as an approach to
predicting the MOA of novel antifungal compounds. To this
end, a collection of structurally related synthetic compounds
with antifungal activity but unknown MOA were examined.
Their proﬁles were highly related to known microtubule
inhibitors and highlighted by marked hypersensitivity of the
TUB1 heterozygote (Figures 4 and 7). Subtle differences in
CaFT proﬁles between these compounds were observed, most
notably the hypersensitivity of BUB1 and ESP1 to one
compound (ECC220), as well as a potential secondary effect
on cortical actin by a second compound (ECC275). These
differences may reﬂect different structure–activity relation-
ships and/or off-target effects between structurally related
compounds, as similarly demonstrated between fenpropo-
morph and related compounds in the ScFT studies [11]. The
primary MOA of these ECC compounds as microtubule
inhibitors was veriﬁed genetically (Figure 8) and biochemi-
cally (Figure S10). First, the representative ECC compounds
phenocopy the genetic depletion and the chemical inhibition
of TUB1; that is, they promote pronounced cell cycle arrest
and nuclear migration defects at early time points and a
subsequent pseudohyphal morphology at later time points, as
reported with nocodazole-treated C. albicans [41]. Second,
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ECC compounds, nocodazole, and benomyl all similarly
disrupt microtubule structures. Third, these ECC compounds
inhibit in vitro microtubule polymerization, indicating their
primary MOA as microtubule inhibitors.
CaFT screening of inhibitory compounds, combined with
recent target validation strategies in both C. albicans [6,53] and
A. fumigatus [43,54], may provide several signiﬁcant advan-
tages to antifungal drug discovery. The CaFT facilitates a
reverse genetic approach; that is, it links traits (responses to
inhibitory compounds) to preexisting mutations (heterozy-
gous deletion strains), potentially on a global scale and within
the major fungal pathogen. Drug resistance mechanisms can
be identiﬁed early and in parallel to MOA determination of
potential antifungal agents. Drug targets are identiﬁed
empirically and are biased towards those with intrinsic
susceptibility to chemical inhibition. Moreover, only subse-
quent to the identiﬁcation of a target–inhibitor interaction is
target validation in key fungal pathogens required
[6,43,53,54]. In this way, compound–target pairs may be
efﬁciently prioritized as antifungal drug leads according to
their chemical attributes, MOA, and target validation
information. In summary, an assayable and comprehensive
target set screened across broad chemical diversity may offer
a new opportunity to identify antifungal agents that are both
mechanistically and structurally novel.
Materials and Methods
Genome annotation. The C. albicans genome sequence at 10.9X
coverage was determined by the Stanford Genome Technology
Center (http://www-sequence.stanford.edu/). A precise genome anno-
tation for C. albicans [3] was not publicly available during the course of
this project. Instead, a list of 7,680 open reading frames (ORFs)
encoding proteins  100 amino acids provided in an earlier release
was used to initiate an internal annotation effort. To select ORFs for
construction of heterozygous deletion strains, only those satisfying
either of the following conditions were initially chosen: 1) ORFs (n ¼
4,068) with clear homologs (BLAST e-value , 1310
 20) at amino acid
level in other fungal species, or 2) ORFs (n ¼ 1,635) with no clear
fungal homolog but   600 nucleotides in length. Recent S. cerevisiae
annotation efforts demonstrate that such rules provide 99% and 98%
conﬁdence of a bona ﬁde gene locus rather than a spurious ORF
[5,55]. The high degree of conservation in gene structure between S.
cerevisiae and C. albicans, including average length, intron structure,
intron-occurring frequency, GC-contents, and promoter elements [3],
strongly reinforces the applicability of such gene-coding ‘‘rules’’ to C.
albicans genome annotations.
C. albicans heterozygote strain construction and the CaFT strain
pool composition. Heterozygous deletion strains were constructed
essentially as in S. cerevisiae, with some modiﬁcations [6,56,57]. Brieﬂy,
individual strains were constructed by replacing the entire ORF of a
particular gene with a cassette of HIS3 gene ﬂanked by distinct
upstream and downstream barcodes, termed up-tag and down-tag,
respectively. Each tag is in turn ﬂanked by two primer sequences that
are common to all the up- or down-tags (Figure 1). The nucleotide
sequences for up- and down-tags, as well as the ﬂanking common
primers, were as used in the S. cerevisiae deletion project [57]. This
conﬁguration provided two very powerful features to these double-
barcoded heterozygote strains: 1) it enables PCR ampliﬁcation of
large numbers of distinct up- or down-tags using two sets of common
PCR primers, and 2) it allows the identiﬁcation of each heterozygote
strain (and the corresponding gene) via the identities (i.e., the
sequences) of a unique pair of up- and down-tags. More speciﬁcally,
PCR ampliﬁcation of a deletion cassette containing a HIS3
auxotrophic marker was performed using 99-nucleotide (nt) oligos
containing 1) 59 sequence of 43 nt directing homologous recombi-
nation at the 59 or 39 of the target gene, 2) internal strain-identifying
unique 20-nt barcodes and ﬂanking common primer sequences for
the ultimate PCR ampliﬁcation of the barcodes in the ﬁtness test
assay, and 3) 18 nt of 39 sequence, which anneals to the 59 or 39 of the
CaHIS3 gene and facilitates PCR ampliﬁcation of the disruption
cassette for transformation. Transformants were genotyped for
correct integration into the target locus by PCR to conﬁrm the
expected 59 and 39 junctions. Genes chosen for disruption were
selected based on prior knowledge that their closest homolog is 1)
known to be essential in S. cerevisiae, 2) a member of a gene family
known to display a growth phenotype when deleted in S. cerevisiae, or
3) conserved in A. fumigatus or other fungal organisms. In total, this
procedure was applied to 2,868 distinct genes, which represented
approximately 45% of the C. albicans genome. They included all the
experimentally demonstrated essential genes we reported previously
[6]. These 2,868 heterozygote strains were cultured individually and
manually mixed in approximately equal proportions to generate a
pool of C. albicans strains, aliquots of which were frozen and used in
all the experiments. Although the full collection of strains comprising
the CaFT is not available at this time, individual strains pertinent to
the proﬁles presented in this study are accessible to investigators,
following the standard Merck Material Transfer Agreement and
clearance procedures.
Construction of homozygous deletion strains. Heterozygous
deletion strains were used to construct homozygous deletions with
the PCR-based method described [6], except that the coding region of
the second allele was replaced by the SAT-1 gene, which confers
resistance to nourseothricin.
Antifungal compounds. Compounds were purchased from Sigma-
Aldrich (http://www.sigmaaldrich.com/), with the following excep-
tions: caspofungin from Merck (http://www.merck.com/), ﬂuconazole
from Pﬁzer (http://www.pﬁzer.com/), and aureobasidin A from Takara/
Fisher (http://www.ﬁshersci.com/). ECC220 is available from AKos
Consulting and Solutions GmbH (Basel, Switzerland; http://www.
akosgmbh.eu/), ECC22 from Interchim (Montlucon, France; http://
www.interchim.com/), ECC248 from ASINEX (Moscow, Russia; http://
www.asinex.com/), and ECC275 from Ambinter (Paris, France; http://
www.ambinter.com/).
The CaFT DNA microarrays. We custom-built a set of two DNA
microarrays using Amersham CodeLink Activated Slides (http://www.
gelifesciences.com/). These microarrays contain DNA oligos identical
to the up- or down-tags, with each oligonucleotide duplicated side by
side. Each array contains 16 sub-arrays (of 16324 spots), for a total of
3,072 duplicated features, corresponding to all the strains in the
CaFT pool, and various controls.
The CaFT experiments and data analysis. For each compound
tested, a prior IC curve was determined using the CaFT strain pool
(with an initial OD600 of 0.025) in liquid RPMI medium (in 96-well
format), grown at 30 8C for 15 h. Based on the IC curve, 5-ml cultures
of the CaFT pool (with the initial OD600 of 0.025) were treated with
the selected compound at multiple concentrations, together with
mocks. After 15 h of growth at 30 8C, the ﬁtness (F) values of
compound-treated cultures were determined, F¼OD(compound-treated) /
OD(mock); that is, the inverse of IC. Cultures of desired F values were
selected and diluted to OD600 0.05 with the medium containing the
compound at the original concentrations. After another 23 h of
growth, all cultures were collected and cell pellets frozen. Following
extraction (MasterPure Yeast DNA Puriﬁcation Kit; Epicentre, http://
www.epibio.com/), genomic DNA preparations from compound-
treated and mock cultures were PCR ampliﬁed with Cy3- or Cy5-
labeled common primers. Labeled tags from compound-treated and
mock cultures were mixed and hybridized against the corresponding
DNA microarray (Figure 1). (The up- and down-tags were ampliﬁed
and hybridized separately.) The intensities of signal were obtained for
each barcode of compound-treated and mock cultures from a single
DNA microarray. They were ﬁrst converted to a log2 scale before
further analysis. For each tag, the log-fold-dropout (LFD) was
computed as the average differences between the mock and the
compound-treated. Following the compilation of results for 57
diverse compounds (referred to as the reference set), a statistical
proﬁle was computed for each tag by modeling the distribution of
LFD as a mixture of a normal component (random variation of the
tag when the strain growth is not preferentially affected by the
compound) and a uniform distribution (representing unusual LFDs
for a given tag). This model was optimized using the EM algorithm
[58], and the parameters of the normal component were stored as a
model of the intrinsic variability of a given tag through the complete
experiment. For any tag in any given experiment, the computed LFDs
are converted to a z-score by using the parameters of the
corresponding tag proﬁle. To facilitate the comparison of experi-
ments with different LFDs distribution, we applied a multiplicative
correction factor to the LFDs that corresponds to 1/rz, where rz is the
standard deviation of the z-scores for that experiment. The z-scores
were then recomputed from these normalized LFDs and are referred
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scores are not converted to p-values and are considered the ﬁnal
quantitative result of the experiment. This approach has the
advantage of accounting for the nonspeciﬁc sensitivity of some
tags/strains to chemical insults and for unexpectedly variable tags/
strains, and thus greatly reduces the frequency of false positives.
Contrary to other approaches (e.g., [59]), our analyses do not rely on a
correlation between signal variability and signal strength, but rather
are modeled on a tag-by-tag basis, taking advantage of multiple
experiments as pseudo-replicates, and rely on the EM algorithm to
identify outliers. We hold that using a set of compound-treated
cultures to establish a statistical model is a superior approach to
using a set of replicated mock cultures since the latter would not
model nonspeciﬁc responses to variations such as growth conditions
and chemical insult (e.g., broadly hypersensitive stains).
C. albicans spot tests. Individual heterozygous strains were ﬁrst
grown in liquid medium (without compound) to OD600 ;2. Cultures
were diluted to OD600 0.2 and transferred to 96-well microtiter plate,
followed by 1:5 serial dilutions. Aliquots (3 ll) of diluted cultures were
spotted onto solid media (YPD) containing 1% DMSO (mock) and
inhibitory compounds at the concentrations indicated with 1%
DMSO. Plates were incubated at 30 8C, and photographed after 2 d
(unless otherwise noted in the ﬁgure).
In vitro tubulin polymerization assay. Cytoskeleton CytoDYNA-
MIXTM Screen 3 (http://www.cytoskeleton.com/) was employed in
these assays, in which puriﬁed tubulin (.99% pure tubulin isolated
from bovine brain, from Cytoskeleton catalog # TL238) was used to
follow the in vitro microtubule polymerization process. To initiate
the assay, different concentrations of ECC85, ECC248, ECC275, or
nocodazole were added to the standard assay solution, which contains
3.5 mg/ml puriﬁed bovine tubulin in 80 mM PIPES (pH 6.9), 1 mM
MgCl2, 1 mM EGTA, 1 mM GTP, 5% glycerol, and 1% DMSO. The
assay mixtures were incubated at 37 8C for 60 min, and the
polymerization process was monitored by turbidity measurements
at OD340 at 1-min intervals.
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